DELCATH SYSTEMS
Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer. The Company's technology, known as Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of anti-cancer drugs to the site of disease without exposing the patient's entire body to those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. PHP is currently undergoing testing in Phase III and Phase II clinical trials for a variety of cancers of the liver.
DELCATH SYSTEMS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1987-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.delcath.com
Total Employee:
11+
Status:
Active
Contact:
2124892102
Email Addresses:
[email protected]
Total Funding:
143.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Apache Sitelinks Search Box Microsoft Exchange Online Organization Schema
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Atlas Venture
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Employees Featured
Stock Details
Investors List
Avenue Capital Group
Avenue Capital Group investment in Post-IPO Debt - Delcath Systems
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Delcath Systems
Official Site Inspections
http://www.delcath.com Semrush global rank: 7.75 M Semrush visits lastest month: 437
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Delcath Systems"
About Us - Delcath
Mr. Muir joins Delcath Systems with 20 years of sales and marketing experience in the biotherapeutics and medical technology industries. Before joining Delcath, Mr. Muir was …See details»
Delcath Systems - Wikipedia
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Pha…See details»
DELCATHSYSTEMS.COM
Delcath Systems, Inc. at 2nd Annual Disruptive Growth & Healthcare Conference February 15, 2017. See All Investor Events and Webcasts. Featured News. Latest News. September 22, …See details»
Delcath Systems - Crunchbase Company Profile
Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer. Its proprietary product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System …See details»
Delcath Systems - Overview, News & Similar companies - ZoomInfo
Mar 18, 2024 Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” …See details»
Delcath Systems - LinkedIn
Delcath Systems Pharmaceutical Manufacturing New York, NY 2,586 followers Delcath Systems, Inc. is an interventional oncology company focused on the treatment of metastatic liver cancer.See details»
Investor Relations - Delcath Systems, Inc.
Nov 8, 2024 Delcath may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means …See details»
Delcath Systems | DCTH Stock Price, Company Overview & News
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was …See details»
Delcath Systems - Leadership Team - The Org
The Leadership Team at Delcath Systems oversees strategic direction and operational execution to drive innovation in cancer treatment. Comprising senior executives from finance, operations, …See details»
Delcath Strengthens Executive Team with Appointment of
NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive …See details»
Delcath Systems Announces U.S. Launch and First Commercial …
Jan 16, 2024 Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, …See details»
Delcath Systems to Participate in Upcoming Investor Conferences
Nov 1, 2024 QUEENSBURY, N.Y.--(BUSINESS WIRE)--Nov. 1, 2024-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary …See details»
Careers - Delcath
See a full list of careers in Delcath and help us revolutionize cancer treatment. About Us; ... (QSR), Medical Device Directive (MDD), International Standards Organization (ISO), …See details»
Delcath Systems, Inc. Announces Promising Results from …
Aug 26, 2024 Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, …See details»
Delcath Systems Reports Fourth Quarter and Full-Year 2021
NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic …See details»
Delcath Systems Reports First Quarter 2024 Results and Business …
May 14, 2024 During and since the first quarter, Delcath: Recognized over $2.0 million of revenue from sales of HEPZATO KIT (melphalan/Hepatic Delivery System) and $1.1 million in …See details»
Our Therapy - Delcath
The blood is filtered through Delcath’s proprietary filters to remove excess melphalan as it leaves the liver, and is then returned to systemic circulation. Delcath’s percutaneous targeted, whole …See details»
Mission, Vision & Core Values of Delcath Systems – CBM
Nov 11, 2024 Delcath Systems is a leading medical technology company dedicated to revolutionizing cancer treatment through its innovative therapies. Our mission is to provide …See details»
Persistence pays for Delcath as cancer treatment Hepzato Kit …
Aug 15, 2023 Delcath's Hepzato Kit is a drug/device combo that administers the decades-old chemotherapy melphalan into the liver through a process called percutaneous hepatic …See details»
Delcath Systems (DCTH) Earnings Date and Reports 2025
Nov 4, 2024 Delcath Systems updated its third quarter 2024 earnings guidance on Thursday, October, 17th. The company issued revenue guidance of $11.2 million-$11.2 million, …See details»